Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights

Biotech SG&A Expenses: ACADIA vs. Soleno

__timestampACADIA Pharmaceuticals Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 2014327480002917513
Thursday, January 1, 2015908040007878291
Friday, January 1, 20161864560008366794
Sunday, January 1, 20172550620006610381
Monday, January 1, 20182657580006556000
Tuesday, January 1, 20193256380006930000
Wednesday, January 1, 20203886610008758000
Friday, January 1, 202139602800010806000
Saturday, January 1, 20223690900009844000
Sunday, January 1, 202340246600013481000
Loading chart...

Unleashing insights

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of ACADIA Pharmaceuticals Inc. and Soleno Therapeutics, Inc. from 2014 to 2023. Over this period, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023, reflecting its aggressive growth strategy. In contrast, Soleno's expenses grew by approximately 360%, indicating a more conservative approach.

Key Insights

  • ACADIA Pharmaceuticals Inc.: From 2014 to 2023, ACADIA's SG&A expenses increased from $32.7 million to $402.5 million, highlighting its expansion efforts.
  • Soleno Therapeutics, Inc.: Soleno's expenses rose from $2.9 million to $13.5 million, showing steady growth.

This comparison underscores the diverse strategies within the biotech sector, where companies balance growth with financial prudence.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025